# Caron A. Jacobson

Source: https://onco.cc/people/caron-jacobson/  
OnCo record `caron-jacobson` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Boston lymphoma doctor who led ZUMA-5, the trial that brought the CAR-T therapy axicabtagene ciloleucel to relapsed follicular lymphoma.

## Summary

Caron Jacobson leads the immune effector cell therapy programme at Dana-Farber Cancer Institute. She was first author of the 2022 Lancet Oncology report of ZUMA-5, the phase 2 trial in which axicabtagene ciloleucel produced high and durable response rates in relapsed or refractory indolent non-Hodgkin lymphoma, the basis for its approval in follicular lymphoma. She also investigates CAR-T therapy in large B-cell lymphoma.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: lymphoma; car-t; cell-therapy; trialist
- Role: Lymphoma specialist and medical director of immune effector cell therapy, Dana-Farber Cancer Institute
- Specialisms: CAR-T cell therapy; Follicular lymphoma; Large B-cell lymphoma

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Marginal zone lymphoma](https://onco.cc/cancers/marginal-zone-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)
- trials: [ZUMA-5](https://onco.cc/trials/zuma-5/)

---
JSON: https://onco.cc/api/v1/entities/caron-jacobson.json